M. Hughes

发表

Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection

M. Niu, S. Liou, V. Johnson, 1996, Annals of Internal Medicine.

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results

R. Yogev, E. Capparelli, J. Rodman, 2008, AIDS.

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.

S. Ray, M. Purswani, D. Persaud, 2007, The Journal of infectious diseases.

Ritonavir-Based Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Infants Younger Than 24 Months of Age

W. Borkowsky, R. Yogev, J. Rodman, 2005, The Pediatric infectious disease journal.

Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection

S. Hammer, D. Katzenstein, C. Spino, 2000, Journal of acquired immune deficiency syndromes.

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group

M J Daniels, M A Fischl, M D Hughes, 1998, AIDS.

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

S. Hammer, D. Katzenstein, R. Schooley, 2000 .

Pharmacokinetics of Saquinavir-SGC in HIV-Infected Pregnant Women

L. Mofenson, E. Acosta, J. Pitt, 2001, HIV clinical trials.

HIV-1 entry inhibitors and virus emergence

V. Johnson, R. D'Aquila, M. Hughes, 1999, Nature Medicine.

Dynamic calibration of pharmacokinetic parameters in dose-finding studies.

J. O'Quigley, T. Fenton, Lixia Pei, 2010, Biostatistics.

Oxidant Stress and Peripheral Neuropathy During Antiretroviral Therapy: An AIDS Clinical Trials Group Study

R. Shafer, J. Morrow, D. Clifford, 2006, Journal of acquired immune deficiency syndromes.

Excellent retention, virologic and clinical outcomes after transitioning from an antiretroviral treatment clinical trial to locally-provided care and treatment in Africa

A. Siika, S. Lockman, J. Currier, 2017 .

Practical Reporting of Bayesian Analyses of Clinical Trials

Michael Hughes, M. Hughes, 1991 .

LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

E. Daar, Davey M. Smith, C. Fletcher, 2021, Open Forum Infectious Diseases.

The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of ⩽ 50 × 106 cells/l

S. Hammer, M. Samore, E. Coakley, 2000, AIDS (London).

Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees

C. Tangen, KyungMann Kim, R. Freedman, 2006, Clinical trials.

Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial.

R. Davey, H. Lane, K. Ruxrungtham, 2019, Clinical Infectious Diseases.

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children.

M. Hughes, J. Lindsey, K. Buchacz, 2001, Pediatrics.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

M. Hughes, S. Gortmaker, G. Seage, 2001, The New England journal of medicine.

Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.

S. Hammer, D. Katzenstein, M. Hughes, 2001, AIDS research and human retroviruses.

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS research and human retroviruses.

A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.

S. Hammer, M. Hughes, S. Suwanagool, 2000, Australian and New Zealand journal of medicine.

Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies.

S. Cohn, J. Eron, K. Patterson, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Meta-analysis for the evaluation of potential surrogate markers.

M J Daniels, M. Daniels, Michael J. Daniels, 1997, Statistics in medicine.

Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children.

M. Cowles, M. Hughes, J. Lindsey, 2000, The Journal of infectious diseases.

Drug development strategies for salvage therapy: conflicts and solutions.

M. J. van der Laan, D. Kuritzkes, J. Schapiro, 2006, AIDS research and human retroviruses.

Reporting Bayesian analyses of clinical trials.

M D Hughes, M. Hughes, M. Hughes, 1993, Statistics in medicine.

Autoregressive models for describing non-linear changes in biological parameters fitted using BUGS.

M D Hughes, A P Mander, S J Sharp, 1999, Statistics in medicine.